Abeona Therapeutics Activates New York Facility as Fifth Qualified Treatment Center for ZEVASKYN Gene Therapy

Abeona Therapeutics has activated NewYork-Presbyterian/Columbia University Irving Medical Center as its fifth Qualified Treatment Center (QTC) for ZEVASKYN gene-modified cellular sheets. This expands patient access to ZEVASKYN in the New York metropolitan area and across the Northeast. ZEVASKYN is an autologous cell sheet-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa.